Cohort Study in Fujian Province

Chronic Disease Clinical Trial

Official title:

Fujian Cohort Study of cARdiomEtabolic Disease and Comorbidity(Fu-CARE)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06102187
• Other study ID #: LYu
• Status: Recruiting
• Start date: January 1, 2017
• Est. completion date: December 31, 2026

Study information

• Verified date: November 2023
• Source: Fujian Provincial Hospital
• Contact: Kaiyang Lin
• Phone: +8613559355708
• Email: lky7411[@]sina.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In this study, Chinese residents aged 35 to 75 years old were recruited from Fujian Province. Physical examination, questionnaire survey and biological sample collection were performed at baseline, and at least 4 years of follow-up were conducted. Information on newly discovered cardiovascular metabolic illnesses and comorbidities was collected during follow-up, and repeated surveys similar to baseline were conducted. To explore the relationship between environment, diet and lifestyle and the risk of cardiovascular metabolic diseases and concomitant disorders.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150000
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 35 Years to 75 Years

Eligibility

Inclusion Criteria:

• Aged 35-75, having lived in Fuzhou, Putian, Quanzhou, Nanping, Xiamen, Zhangzhou, Longyan, Sanming, or Ningde in Fujian Province for more than 6 months.

Exclusion Criteria:

• Anyone diagnosed with coronary heart disease, stroke, or cancer.

• Anyone with a severe disability who is unable to participate in the study.

Related Conditions & MeSH terms

• Chronic Disease

Locations

Country	Name	City	State
China	Fujian Provincial Hospital	Fuzhou	Fujian

Sponsors (3)

Lead Sponsor	Collaborator
Fujian Provincial Hospital	Center for Disease Control and Prevention, Fujian, China National Center for Cardiovascular Diseases

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Coronary Disease	It is a form of myocardial ischemia (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. At the follow-up, the outcomes of coronary events were acquired. Coronary CTA examination and coronary angiography were the primary measuring modalities.	5 years
Secondary	other metabolic diseases	Including hypertension, stroke, diabetes, impaired glucose tolerance, obesity, cancer, chronic obstructive pulmonary disease and chronic kidney disease. These disorders were diagnosed using international standards, and the necessary information was gathered during face-to-face follow-up.	5 years